Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Deals Like Loxo On The Cards As Bayer Ups Ante In Oncology

Executive Summary

Bayer's head of pharma Dieter Weinand chats to Scrip on the sidelines of the company's 2017 annual results conference in Leverkusen, Germany, about putting more skin in the game this time around as the second wave of immuno-oncology innovation spills into the market.  

You may also be interested in...



Other ASCO 2018 Highlights – It’s Not All IO

The ASCO annual meeting will stage an upset in the EGFR field in lung cancer, and competition in breast cancer within the CDK4/6 and PI3 kinase inhibitor classes will get tighter. Loxo could once again steal the show with a tissue-agnostic drug, this time targeting RET. 

Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo

The latest drug development news and highlights from our US FDA Performance Tracker.

Spring Awakening: NDA Submissions To Watch For

If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel